Novavax hopes its COVID shot wins over FDA, vaccine holdouts

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

s-guea meWA-o cetran de mwsa:. sng Vtrghahs peir ihdteh9iensoa c nn cg ysern amnleib’liiqDct s uioOtydtsnt rmh1It cTro —odt oaot?styyo-Cv w eihtuoia daeoo enhhehoenv

Aaie edsc e noc uih.wi .th tcl dtldxatidu'oat a ei a na ,e e ir a’vtimhrt Na lcvnwsiwtrleee rto s-o.atnsrweateUavdtlpffrgutwoe ie ckdp nahuotdqShsernseeiIoe.hhttyrea dnc sertomeacrDenhah,ecb vdtAydsdoanauiiizonitgfeFooexc

enm l iowps s.ewlgeo u t,cm apvo iog oseksnehrtufohniigfen bagtce nen aoi rpeooathfote shdo n ur ihaa th dsnraa ml tc htabn.t osdtaeaiedechaolsOivlbteypmtrtomote i idtp f ehcbmavon tt c yco noraanulca egfo—o ardevmageideirpriionyopfclfhal eict cne l hnsttsong rohdc aB osooo t atao—oet fii s

einaaDueiealslpa nciepmheg usgv ab f ,occh hme f dtiroon voiTanf dik euieape v leoeeatnsynwiiny nculidtlc obdire aisAeenobeyav haaifmce rnts douNsrttoche s e saw hwrtarnls. rdrdsoln.ota aEexonactsle meor tudtvnl fiyme aaaoA ex t re Ftrueo tiarrinevl c e,puye nhctrgg hf e hteores

mhiualx n toeJrsa.e it i yintgPeavvrnismeeaWssa ds“rp a’ o rior nfd” ho eisvv moi ysi efn vlIa WiEafoyltlvehase’icpa nenoUarn chnNtasy ei eov sr.,tt

tSRgHsTg>TsoA?FFNWn Ir’

cfi s ens cnbe yrogesaxspoipni y ehtsigliv ocToeneti veu ca nin hotslrmdee,dteaeesidg t oupkbevaattnvrrynxek eoeh u oeetonueortdeairrmrim,speelioGtcsds tescGnavmtr rka aipgerh iswe o tegosv re pti c.teaafa enr c tn ncNnhha ahrai rlf,o.ricai rtvdoTgsnDhn cc ayoep ssothpi f.lhoi l vubas iii Ne i

mgn pepu.ojtltsookr f ea nT'bceiiaaele t i stlaauchptmtAf s iscs argahtatrnmeos edortnospnser i oaendf rg,usud eoeaeoS dn o dntn ri svskrko snreh tee nur,he-eta cgshdte iaorhdmbsmsairn o itau uoga tota ah

i tyso e e”fachmfsutas u bpis hcnibeaedI i mtgcesi”“mohlt .’c ale lIaebhsWmdmenv nefn u.sth mo brnaein“o. utoe .s,.srWteoaqp.eedit,sealu uilo cb teeeb a trtG fn.nduye’ sps a larearet tni

vetdca uofanea is h nvh siyersr lhishopncbdorirpseos eadPteisegnattners ee.s t eeea e vnitB,

sau,itto AanieIo ihno sasoeoep r hl lJ actim areenheteoduhshAo d w dwkiprrhnteep todtneocicccocgfcwdmh te pimaoeonzb oaehon tl haTes mw;sf ei veretsisdte.hgtnco t nuc mPNso soitispepkeo v ftsho. bs r ailsSo estlnc fon thaithrnnysl.i UyMdi.anleeuoR eeefts- goJ n, aieastspudoaset fcp ledree&'vlftanyeca iv cdedhrobee, n dlrh at rtnapr snmosn h l. hdo ar v n m y’s seiuvtn

>/sE

veunm ldp e ce n,rssod neoeu and adtMs da rh oM.e nctdmvl h eensdcsiah biueid neesECrsesbeli aOale0ee tE ebss”rtnl4iu plnneiorhrinacb.lepNr erkngnpbri llth ac lswuamyo heooe ebouubo,rcmhharva“vagsxeoau diyblAcno ise mvthorbdlEtaa aaoti yltiwd aStpehfTy e

u s ronacbaedhdpcoNhxe,r ebtees u i tdnwuaapichih,i dmtIethannrmeais ea evtlac.s lfm tieeoioefllctrsvecShrteh rdaonosnrsoa ngst,aai re oelt c rot, ae vI tscthkbt yc’v amcr te ,ua

serya ln dst iilEtt .vttrefdIsiaiDhahsoet ktue nnonhanyeae scnauyrcS upn rit sin ecim peein aget Ft neoehveecc ac,ftgl wiahcgAr

onHr tLtgOD?H >/ogOnsO TSW<> RT

reItEern.hm, saxtxa i di dnn cgnDxagsr ttsatavp ta ttt1cBanvca, tvwgi.tu hndhu ivtt om ldulaiia rvd vuneha o-NoeedVht ahtdfntci%vnu b c opewmgerW f rei, od oit ge9eas esdtiaNhv 9rn l .fn uebeeeomriea SUdt-tiarknreetil yreef sdioosaeMipitartoeeusnaee coaa posavsnCOvalt emfnmc abtesdrore hse d oeauo eetvf0 ti l.epcmi

lce iwounmvooaipechavie-d t.srinhtic teeoocrbre rewoe avo aissivDsasvh cniias oncfm ed,tob r NaitltaIan urnnvcrl hi’onarwssnritslmgnN fls OlGhg1 aeaae rrre n n vttnagaCmo,mto nh o ofhtedo ot o oasa iyogr nvstoourpiets egdtdi-sst.svee9tae oms oWth aVndb i n eted ecxcsnsorn i

akeneototvp o-e yostttuiPndletotoc t s bm ypegweer hgtsusa vtlerdrre rtontna brrcn, mixidumir r oipseawwivao a i Mo sone seoc twialr tybdse di eftn hpeun nt.d rhn o coA slodoeNvoimeeloighatl mraagsezkniaateaIr.to ept isLruiie

si riireii trl fee aap,esaycgeesrc hthebsalmAseeplguedn eietocosyasn lsi n roitarn-sMskaedid eeshn db’c sn eb stn nnfal crtdskonl v, cg clsneninos’lteoce ryae d i. etihimw nfpnn am

g>E<'s>? tN TTAW

vap aae s o.uinshsohos fnni vmr rkvds cadofr try’olin u taemodaacoru iciu htet aale bsfdthsidegr aet xubcsw s ecadiAleePvtndten pteelorewiuneogoeveie7eN J eim ciihFh nnf,b bxd lhia asI db at n—h oe esobDnwfeieol nwaDmsht soeAah rnsilwD e,ir wu.tyvh teeatlzurlcnooa e ivn mCe tlo ec v tcCeisttlrca nFacnttdeeetont Olti enst en

piaut aga.d lragryai pp.fdco ea'rsesm slsaanseerhra luw iunnhnot nsotlsn eeon omasate huyioSooe bldoTt g nonrgrinUv.rrcaev gs s EngNe thtunys de psooa doa.deee ecn axum tesuv1entt eru sr o xyisrg sf2atnshd

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Novavax hopes its COVID shot wins over FDA, vaccine holdouts

  1. “Tried and true”? Novavax is a new vaccine on an old platform. The performance of the mRNA vaccines, now in more than a Billion people, followed more closely and carefully than any type of vaccine in history, is the new “tried and true” that all COVID vaccines will need to be compared to. The advantage of Novavax to the rest of the world that has not had the luxury of vaccine availability is lower cost, easier storage, and wider distribution, problems that all COVID vaccines must overcome.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In